DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Industry Headlines

IMAGE Information Systems releases iQ VIEW PRO 3.1 Can identify relevant priors in 1-2 seconds in PACS of more than one million studies

Trump administration halts tariff proposal on Chinese imports... for now The 25 percent tariffs get placed on the back burner

Is low cost Proton-to-Carbon Heavy Ion radiotherapy coming soon? Best Particle Therapy plans to bring smaller footprint system to market in two to three years

'Fake Cerner' MR fraud conspirator pleads guilty, has fatal seizure same day Suresh Mitta passed away within hours of going into custody

Coalition urges CMS clarification on low dose CT guidance Coverage regularly excluded when performed at independent imaging facilities

Gaining the experience advantage In the digital economy, value needs to be evaluated through the eyes of the customer

New algorithm predicts impact of heart transplants on survival in heart failure patients Acquires information based on 53 data points to predict rate and length of survival

Change Healthcare unveils InterQual 2018 Supports decision-making by providing updated and enhanced clinical criteria

NHS surgeons use 3D printing to perform lifesaving kidney transplant Stratasys technology used to plan operation on two-year-old boy

MRI Interventions and Voyager Therapeutics partner on Parkinson's therapy Bringing real-time MR guidance to minimally-invasive neurosurgical devices

Strand Diagnostics biopsy kit

How safe are breast biopsy samples?

by Loren Bonner , DOTmed News Online Editor
Personalized medicine -- specifically tailoring medicine to someone's own DNA -- is fueling innovative approaches not just to treat breast cancers, but also to ensure correct diagnosis among biopsied women.

"We're entering an era of personalized DNA medicine where everyone in the future will have their breast cancer tested to ensure that, first, it was their cancer and second, to tell them if chemotherapy is needed [prognostic], lastly it will help tell us which type of chemotherapy is best-suited for their cancer, based on DNA testing," Dr. Andrew Kenler, a Connecticut-based breast surgeon at the Norma F. Pfriem Breast Care Center, told DOTmed Business News.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



While breast cancer therapy based on DNA may not be available clinically for some time, a new system to protect breast biopsy patients from inaccurate diagnosis due to misidentification of biopsy samples is already being used at a few select cancer centers around the country.

Dr. Kenler was one of the first physicians to incorporate the "know error" breast biopsy kit, from the Indianapolis-based Strand Diagnostics, as a standard part of his breast biopsy protocol at the Norma F. Pfriem Breast Care Center, which is affiliated with the Yale New Haven Health System in Bridgeport, Conn.

According to Kenler, the results of one in 100 breast cancer diagnoses is a DNA-non match. "That is to say that of the approximately 300,000 breast cancers that are found annually, roughly 3,000 biopsy results will be a DNA-non match [false positive]," he said.

After a biopsy sample is taken from a patient, it typically travels through a lengthy process -- roughly 20 steps -- usually in multiple locations and with multiple providers.

Kenler said the most common medical errors occur when the specimen is mislabeled either in the doctor's office where the core breast biopsy is done or in the pathology lab. The second most common error that can lead to false positive breast biopsies occurs when the specimen is contaminated in the pathology lab during the routine biopsy evaluation process, he said.

Strand Diagnostics, which also makes a testing kit for prostate biopsies, developed the breast biopsy system based on patient-specific bar coding and forensic chain-of-custody principles as well as DNA Specimen Provenance Assignment or "DSPA" testing. According to a statement from the company, the DSPA test verifies patient identity at the molecular level by comparing genetic profiles obtained from the patient's biopsy tissues and a DNA reference sample, taken via cheek swab at the time of the biopsy procedure.

"Determining whether chemotherapy is needed or which type of chemotherapy is best suited cannot be done unless you definitively know that the cancer belongs to the patient in question," said Kenler.

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED